These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26077360)

  • 41. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
    Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
    Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Why methylation is not a marker predictive of response to hypomethylating agents.
    Voso MT; Santini V; Fabiani E; Fianchi L; Criscuolo M; Falconi G; Guidi F; Hohaus S; Leone G
    Haematologica; 2014 Apr; 99(4):613-9. PubMed ID: 24688109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting DNA methylation.
    Issa JP; Kantarjian HM
    Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
    Ball B; Zeidan A; Gore SD; Prebet T
    Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decitabine.
    Hackanson B; Daskalakis M
    Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?
    de Witte T
    Lancet Haematol; 2019 Apr; 6(4):e170-e171. PubMed ID: 30926075
    [No Abstract]   [Full Text] [Related]  

  • 47. [Application of DNA methyltransferase inhibitors for myelodysplastic syndrome].
    Lü XY; Du YX; Dai ZH; Liu M; Liu XY; Zhang KL
    Yi Chuan; 2013 Feb; 35(2):136-40. PubMed ID: 23448925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
    Wu L; Shi W; Li X; Chang C; Xu F; He Q; Wu D; Su J; Zhou L; Song L; Xiao C; Zhang Z
    J Transl Med; 2016 Mar; 14():66. PubMed ID: 26944860
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
    Peng J; Hasserjian RP; Tang G; Patel KP; Goswami M; Jabbour EJ; Garcia-Manero G; Medeiros LJ; Wang SA
    Leuk Lymphoma; 2016; 57(4):812-9. PubMed ID: 26293512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of decitabine in the treatment of myelodysplastic syndromes.
    Atallah E; Kantarjian H; Garcia-Manero G
    Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
    Khan H; Vale C; Bhagat T; Verma A
    Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA methyltransferase inhibitors: class effect or unique agents?
    Griffiths EA; Gore SD
    Leuk Lymphoma; 2008 Apr; 49(4):650-1. PubMed ID: 18398728
    [No Abstract]   [Full Text] [Related]  

  • 56. Decitabine: in myelodysplastic syndromes.
    McKeage K; Croom KF
    Drugs; 2006; 66(7):951-8. PubMed ID: 16740014
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature].
    Gao Y; Ping B; Zhou S
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Feb; 32(2):280-2. PubMed ID: 22381778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
    Ishikawa T
    Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf JP; Zeidan AM
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).
    Silverman LR
    Oncologist; 2001; 6 Suppl 5():8-14. PubMed ID: 11700387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.